Netakimab (BCD-085) is a novel humanized monoclonal IgG1 antibody that binds to the protein interleukin (IL)-17A and IL-17F and inhibits IL-17A in therapeutic concentrations. The antibody is based on llama immunoglobulin with a unique structure containing 2 heavy chains only. During “smart humanization”, llama amino acid sequences remained only in the CDRs; human light chains were added to the antibody structure. This ensured maximum drug affinity for IL-17 and low immunogenicity.

Netakimab is already approved in Russia for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis and active ankylosing spondylitis.

The application for registration of netakimab on the international markets is being prepared.